"The stock is still “dramatically undervalued,” Mr. Kolbert said, noting that it should reach $10 a share within a year.
But if Athersys produces strong data in its Phase II trials, the company could blow away his $10 target, he said. Even $100 a share would be feasible if the stroke technology becomes a widely available product, Mr. Kolbert said, given that about two million people have strokes each year in the United States, Europe and Japan. Mr. Kolbert estimates Athersys would sell MultiStem treatments for $25,000 or more."
It "should" reach $10 within a year. Well, technically, from the date of that article, those pumpers have about a week and a half left. Fat chance.
http://www.crainscleveland.com/article/20140113/FREE/140119942/investors-perk-up-to-promise-of-athersys
Article I, Section. 10. No State shall...make any Thing but gold and silver Coin a Tender in Payment of Debts;...or Law impairing the Obligation of Contracts [ask GM bondholders!].
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM